Fig. 3.

¹⁷⁷Lu-LNC1004 radioligand therapy combined with anti-PD-L1 immunotherapy synergistically enhances antitumor efficacy. a Illustration of the therapeutic regimen and treatment timelines for mice bearing MC38/NIH3T3-FAP and CT26/NIH3T3-FAP tumor models (n = 8/group). b Individual tumor growth trajectories of MC38/NIH3T3-FAP tumor-bearing mice across diverse treatment groups. c, d Tumor growth and survival rate graphs for MC38/NIH3T3-FAP tumor-bearing mice in the four distinct treatment groups. e, f Tumor growth and survival rate graphs for CT26/NIH3T3-FAP tumor-bearing mice in the four different treatment groups. g Histological examination of resected tumor tissues from MC38/NIH3T3-FAP tumor-bearing mice, featuring hematoxylin & eosin (H&E) staining and immunohistochemical staining for Ki-67, TUNEL, CD4, CD8, and GZMB posttreatment. Scale bar: 200 μm